Tag: Aytu BioScience stock

  • Aytu BioScience, Inc. (NASDAQ: AYTU) stock dipped in the After-Hours after this news

    Aytu BioScience, Inc. (NASDAQ: AYTU) stock dipped in the After-Hours after this news

    Aytu BioScience, Inc. (NASDAQ: AYTU) stock slipped in the after-hours market session on Friday as it revealed, due to surging demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 4,166,667 shares of common stock of the Company, at a price to the public of $6.00 per share, less underwriting discounts, and commissions.

    The offering’s closing date will be around December 15, 2020, provided customary closing conditions are satisfied.

    The Company has also granted the underwriter the right to purchase up to an additional 625,000 shares of the Company’s common stock at the public offering price, minus the underwriting discount and commission.

    In total, after deducting underwriting discounts and commissions and offering costs and assuming no exercise of the underwriter’s option to purchase additional common stock, the gross proceeds to Aytu should be approximately $25.0 million.

    The net proceeds from this offering will be used for working capital and other general corporate purposes.

  • Why are Neos Therapeutics (NEOS) shares breaking all barriers in the pre-market session?

    Why are Neos Therapeutics (NEOS) shares breaking all barriers in the pre-market session?

    Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical corporation focusing on the marketing of new drugs targeting critical medical needs, and Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial pharmaceutical company that develops and manufactures products focused on the central nervous system, recently confirmed that they have entered into a definitive agreement in which Neos would merge with Aytu’s wholly-owned subsidiary in an all-stock deal.

    Neos Therapeutics, Inc. (NASDAQ: NEOS) stock price rose 71.72% to reach $0.950 in the pre-marketing session after this report.

    The merger will result in each Neos stockholder receiving 0.1088 shares of Aytu’s common stock for each share of Neos common stock held, including a one-for-ten reverse split of Aytu’s common stock on December 8, 2020. News stockholders will own approximately 30% of Aytu’s fully diluted common shares following the transaction. On a fully diluted basis, the all-stock transaction is valued at roughly $44.9 million based on the 10-day volume-weighted average price of Aytu shares for the period ended December 9, 2020.